Published Date: 15 Apr 2024
One-third of patients experience responses when using adagrasib plus cetuximab, with a median overall survival of 15 points 9 months.
Read Full NewsTopline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.
Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.
Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.
FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy
AI Tools Fall Short for Dietary Recommendations for Managing IBS
Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo
Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs
1.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
2.
Why preventive mastectomy isn't offered to everyone at risk
3.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
4.
Patients with head and neck cancer who cannot receive cisplatin now have new hope.
5.
AI innovation unlocks non-surgical way to detect brain cancer spread
1.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
2.
Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern
3.
Unlocking the Secrets of Leukemic Stem Cells: A Path to Better Blood Cancer Treatments
4.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
5.
Cutting-Edge Cancer Care: The Precision Revolution in Surgical Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation